Science 37 and PhysIQ Collaborate to Enhance Clinical Trial Data Collected from Connected Devices
Collaboration will yield objective, predictive, and real-time digital measures—supplementing clinical trial digital endpoints collected from biosensors
Science 37, an innovator in clinical trials and physIQ announced a collaboration to help research sponsors use remote biosensors and machine learning to build more robust data sets. This will help increase the number of digital biomarkers and generate insights from continuous data streams to more quickly and objectively demonstrate the safety and efficacy of treatments.
“Strengthening our centralized network of data and devices helps fuel our unified technology platform and overall Operating System – enabling us to more effectively deliver today’s more agile clinical trials,” said Elisa Cascade, Chief Product Officer of Science 37. “Partnering with physIQ enhances our OS and empowers us to better identify the specific signals within data collected from biosensors and other connected devices to provide sponsor with more predictive biomarkers.”
physIQ’s robust platform scalability, near real-time capabilities, established FDA clearance, and proven ability to support large global clinical trials strengthen Science 37’s ability to support additional novel digital biomarkers, advance clinical events detection and provide more proactive safety monitoring. physIQ enables Sponsors to efficiently identify valuable digital measures from large amount of noise inherent in biosensors.
“With nearly 1,500 wearables studies in 2020, biosensors and digital endpoints are becoming a standard component of clinical trials,” said Gary Conkright, Chief Executive Officer at physIQ. “Continuous biosensor data is unique and requires specialized digital infrastructure to operate at scale. We are thrilled to partner with Science 37 to deliver on the potential of faster, better clinical trials. Together, physIQ and Science 37 will provide clinical trial sponsors with faster access to real-world evidence to better evaluate and quantify the safety and efficacy of their products.”
